ArticleCancer drug resistance (Alhambra, Calif.)2021

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.

Xin Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.